Trisomy 21 (T21) causes the condition known as Down syndrome (DS), with clear impacts on brain development and function. In a previous paper (Sullivan, 2016) we showed that T21 consistently activates the interferon (IFN) response, but the contribution of IFN hyperactivity to DS phenotypes awaits elucidation. Here, we report the results of a large plasma metabolomics study, showing that T21 disrupts tryptophan catabolism toward increased production of kynurenine (KYN) and its neurotoxic derivative quinolinic acid. We also show that stimulation of IFN signaling leads to tryptophan depletion, over-production of KYN, and super-induction of IDO1, the ratelimiting enzyme in the KYN pathway, in human cells with T21 and a mouse model of DS. Finally, cytokine profiling revealed a positive correlation between circulating levels of IFNα and KYN dysregulation in people with DS.
INTRODUCTION.
Down syndrome (DS) is caused by triplication of chromosome 21 (trisomy 21, T21), which occurs in approximately 1 in 700 live births, representing the most common chromosomal abnormality in the human population (1) . T21 impacts multiple organ systems during development and causes an altered disease spectrum in people with DS, significantly increasing their risk of developing Alzheimer's disease (AD), leukemia, and numerous autoimmune conditions (1-7), while protecting them from solid malignancies (8, 9) . However, DSassociated phenotypes are highly variable among individuals with DS, even for conserved phenotypes such as cognitive impairment and predisposition to early onset AD (2, 10) . Therefore, a deeper understanding of the mechanisms driving such phenotypic variation could illuminate not only mechanisms of pathology, but also opportunities for diagnostics and therapeutic strategies to serve this special population.
In order to identify molecular pathways that could contribute to both the altered disease spectrum experienced by the population with DS as well as the inter-individual variation among phenotypes, our group previously analyzed transcriptomes (11) and circulating proteomes (12) from several cohorts of individuals with DS compared to euploid individuals (D21, controls). These efforts revealed that multiple cell types from people with T21 show transcriptional signatures indicative of constitutive activation of the interferon (IFN) response (11) , which could be explained by the fact that four of the six IFN receptors are encoded on chr21 (13) . Furthermore, plasma proteomics analyses demonstrated that people with DS show signs of chronic autoinflammation (12) , including elevated levels of potent inflammatory cytokines with known ties to IFN signaling (e.g. IL-6, TNF-α).
However, it remains to be defined how this obvious immune dysregulation contributes to highly variable DSassociated phenotypes, including the diverse neurological manifestations of T21. To gain further insight into this area, we investigated metabolic changes caused by T21 in the plasma of people with DS.
Here, we report the results of the largest plasma metabolomics study of individuals with DS to date using untargeted, highly sensitive liquid chromatography mass spectrometry (LC-MS) technology. We discovered dysregulation of a number of inflammation-associated metabolites, such as succinate and 2-hydroxyglutarate (14, 15) , in individuals with DS. However, most prominent among the dysregulated metabolites were those related to tryptophan catabolism. Specifically, people with DS showed highly statistically significant upregulation of kynurenine (KYN) and its neurotoxic derivative quinolinic acid (QA) (16) . Using an unbiased, machine learning approach to build a predictive metabolic signature of T21, we found that select metabolites in the tryptophan pathway, along with other inflammation-associated metabolites, can accurately distinguish plasma from individuals with DS from euploid controls. Using cell-based metabolic flux assays, we found that IFN-α stimulation leads to profound depletion of tryptophan in T21 cells, along with markedly increased production of KYN, which could be explained by overexpression of IDO1, the rate-limiting enzyme in the KYN pathway and a known interferon stimulated gene (17) . We found that a mouse model of DS that includes triplication of the IFN receptor gene cluster, Dp (16) 1/Yey, has increased levels of KYN relative to wild type littermates, and produces more KYN when injected with the IFN-stimulating molecule poly(I:C). Given the well-established roles of KYN dysregulation on a wide range of neurological conditions (18) (19) (20) , our results suggest that IFN-dependent activation of the KYN pathway could contribute to key neurological phenotypes in DS.
RESULTS.
Trisomy 21 causes consistent changes in plasma metabolite abundance.
In order to identify metabolic pathways that are consistently dysregulated by T21, we collected plasma samples from two fully independent cohorts: the Translational Nexus Clinical Data Registry and Biobank (referred hereto as Cohort 1), and the Crnic Institute's Human Trisome Project (www.trisome.org, NCT02864108, referred hereto as the Cohort 2). Cohort 1 included 49 individuals with T21 and 49 euploid (D21) individuals, while Cohort 2 consisted of 30 T21 and 41 D21. The breakdown of patients according to age and sex are reported in Table 1 . While the Cohort 1 is balanced for karyotype but imbalanced for age, Cohort 2 is more age-balanced, with a bias towards females in both D21 and T21 groups. When the two cohorts are combined, age, sex, and karyotype are more evenly distributed, which prompted us to analyze the cohorts both individually and in combination. Because the variables of age, sex, and cohort-specific features (e.g. protocol for sample collection, processing and storage), can influence metabolite abundance and/or detection, we accounted for these variables when determining the impact of karyotype as described below.
To determine metabolite abundance, we performed untargeted, LC-MS metabolomics on plasma from each cohort. The combined analysis workflow is outlined in Figure 1 -figure supplement 1A with details available in the Materials and Methods. This approach led to the identification of 91 high-confidence metabolites detected in both cohorts. To identify those that are consistently differentially abundant between people with and without DS, we employed a robust linear model-fitting approach that accounted for age, sex, and cohort (21) .
We arrived at this model after evaluating each of these variables in the cohorts individually, as well as in combination. Using the 91-metabolite panel, we first evaluated the impact of age and sex within each cohort. We fit linear models and compared the results within Cohort 1, where we included or excluded the variables age and sex directly in the model (Figure 1 -figure supplement 1B) . We found that taking age and sex into account directly impacted the differential abundance statistics when comparing T21 to D21 individuals; this result was expected given the differences in age and sex seen in Cohort 1. We performed the same comparison within Cohort 2 (Figure 1 -figure supplement 1C ) and found similar results, although age and sex had less of an impact as Cohort 2 is more balanced. The differences observed between cohorts motivated us to evaluate the impact of a combined cohort analysis, with the goal of mitigating the biases within each of the individual cohorts and increasing our statistical power with a greater number of individuals.
Integrating data across cohorts required us to evaluate the impact of each cohort as a batch effect. over 80% of the trained models with an accuracy > 0.9. This analysis yielded 11 metabolites, of which eight had positive model coefficients and three had negative model coefficients ( Figure 2B ). These 11 metabolites included seven of the 16 most differentially abundant metabolites and an additional four from the remaining 75 metabolites in our analysis, demonstrating that this approach is not simply selecting the most differentially abundant metabolites, but rather the model is selecting the groups of metabolites that together provide the strongest predictive power. The most frequently selected metabolites included three members of the tryptophan metabolism pathway: QA, KYN, and 3-indole-acetaldehyde ( Figure 2B ). Of note, these three metabolites were selected in 100% of models with > 90% accuracy, while acyl-C5:1 had the largest median positive model coefficient. Next, we evaluated the predictive power across the combined Nexus and HTP cohort using the selected most predictive 11 metabolites. We performed a bootstrapped analysis using a lasso regression to benchmark model performance. We split the combined cohort to train the model on 80% of the participants (randomly selected) and tested performance using the held-out 20%. We repeated this process for 10,000 iterations and found an average model performance of AUC=0.88 with a 95% confidence interval of [0.76, 0.97] ( Figure 2C ).
These results demonstrate that there is strong predictive power within a small group of plasma metabolites for stratifying T21 individuals from D21 individuals. Also, using an independent methodology, these results confirm that differential tryptophan metabolism is a major contributor to the distinguishing metabolic profile of people with DS, which prompted us to investigate this result in more depth.
Trisomy 21 induces the kynurenine pathway.
In vertebrate cells, there are three major catabolic pathways for tryptophan, leading to the production of serotonin, KYN, or indole (Figure 3 ). There is a 10% decrease in L-tryptophan levels in individuals with T21, though it does not rise to the level of significance (p = 0.05, adjusted p = 0.12) (Figure 3 , Supplemental File 1A). There is also an approximately 10% decrease in serotonin, which is not significantly different between T21 and D21. However, 5-hydroxyindoleacetate (5-HIA), a breakdown product of serotonin, is significantly elevated in the group with T21 (adjusted p = 3e-3) (Figure 3) . Conversion of tryptophan to KYN represents a major pathway for catabolism of ingested tryptophan, accounting for removal of up to 99% of this amino acid that is not used in protein synthesis (29). Remarkably, KYN itself and the neurotoxic downstream product QA, are significantly elevated in people with DS (Figure 3) . In contrast, picolinic acid (PA), a neuroprotective derivative of KYN, is not different between the two groups (Figure 3) . Kynurenic acid (KA), another neuroprotective metabolite in the pathway, was detected only in Cohort 2 and was not affected by karyotype (Figure 3 -figure   supplement 1A) . Accordingly, the KYN/tryptophan, QA/PA, and QA/KA ratios are all significantly higher in people with DS (Figure 3 -figure supplement 1B-D) . Notably, indole and its derivative indole-3-acetaldehyde, both of which are significantly decreased in the T21 group (Figure 3) , are metabolites produced from tryptophan by tryptophanase-expressing gastrointestinal microbiota (30, 31). Interestingly, indole can also be employed by the gut microbiota to synthesize tryptophan in a reaction that consumes L-serine (31), an amino acid that is significantly depleted in the plasma of people with DS (Figure 3 -figure supplement 2) . Thus, lower levels of indole and L-serine could be interpreted as a sign of increased tryptophan biosynthesis by the gut microbiome to sustain levels of this essential amino acid when it is shunted into the KYN pathway in people with DS.
Altogether, our results indicate that a major metabolic impact of trisomy 21 is a dysregulation of tryptophan catabolism toward increased production of the neurotoxic metabolites in the KYN pathway. This is an important result, because activation of the KYN pathway has been implicated in myriad neurological and neurodegenerative disorders. Repeatedly, elevations in the KYN/tryptophan ratio, QA/PA, and/or QA/KA ratios have been linked to the development of neurological conditions such as Alzheimer's disease (32-35), Huntington's disease (36, 37), AIDS/HIV-associated neurocognitive disorder (38-40), Parkinson's disease (41), amyotrophic lateral sclerosis (42, 43), and multiple sclerosis (44, 45).
Trisomy 21 sensitizes cells to super-induction of the KYN pathway upon IFN stimulation.
In order to further investigate the mechanism of KYN dysregulation in DS, we employed cell-based metabolic flux experiments using isotope-labelled tryptophan on a panel of age-and sex-matched skin fibroblasts with and without T21. Of note, the rate-limiting step in the KYN pathway is the conversion of L-tryptophan into N-formyl-kynurenine, a reaction catalyzed by the tryptophan 2,3 dioxygenase 2 (TDO2) enzyme in the liver or the indoleamine 2,3 dioxygenases 1 and 2 (IDO1-2) enzymes elsewhere (17) . Importantly, IDO1 is a wellrecognized IFN-stimulated gene (ISG) whose expression can be induced by Type I (α/ β) and Type II (γ) IFN ligands (46-50). Given our previous finding that T21 fibroblasts are hypersensitive to IFN-α, β, and γ stimulation To test the impact of various groups of genes encoded on human chr21 on tryptophan metabolism, we employed three cytogenetically distinct mouse strains carrying segmental duplications syntenic to human chr21 (51): Dp(10)1/Yey (Dp10), Dp(16)1/Yey (Dp16), and Dp(17)1/Yey (Dp17), which have triplication of ~35 genes from mouse chr10, ~120 genes from chr16, and ~20 genes from chr17, respectively, and compared them to wild type C5Bl/6 mice (WT). We prepared plasma samples from age-and sex-matched cohorts comprised of these strains and measured kynurenine using LC-MS. Interestingly, we found that the only strain with significantly increased plasma KYN levels relative to WT mice was the Dp16 model, which is not only the largest segmental duplication, but the one harboring the four IFN receptors homologous to those found on human chr21: Ifnar1, Ifnar2, Ifngr2, and, Il10rb (Figure 5A) . Furthermore, we and others have previously shown that not only are the IFN receptors overexpressed in this model, but downstream IFN signaling is chronically activated on numerous tissues including blood and brain (11, 52) . Therefore, we focused exclusively on this model in subsequent studies. To determine the impact of further stimulation of IFN signaling on altered tryptophan catabolism in Dp16 mice, we chronically injected age and sex-matched Dp16 and WT mice with the synthetic dsRNA Recently, we reported the results of the largest plasma proteomics study of people with DS to date (12) , which revealed that T21 causes changes in the circulating proteome indicative of chronic autoinflammation, including elevated levels of many cytokines acting downstream of IFN signaling. Hence, we decided to test whether there was a correlation between inflammatory markers and KYN dysregulation. Toward this end, we measured a panel of 38 cytokines using a Mesoscale Discovery (MSD) assay in 37 participants in Cohort 2, 18 of them with DS, the other 19 being mostly age-and sex-matched typical controls. We calculated Spearman's correlation between specific metabolites of interest versus all cytokines measured. Strikingly, the top cytokine positively correlated with KYN levels among those with DS was IFN-α2a (ρ = 0.67, Figure 6A ). In fact, most of the cytokines positively correlated with KYN levels (ρ > 0. Once again, most positively correlated cytokines (ρ > 0.3) are known to act downstream of IFN signaling (55-69). As for KYN, the correlations were unique to or more pronounced in people with DS (see for example MCP1 and MCP4 (Figure 6E,F) ).
Altogether, the combination of correlative studies in plasma samples and cause-effect relationships using cell-based assays support the notion that dysregulation of tryptophan metabolism in DS is driven by hyperactive IFN signaling downstream of T21.
DISCUSSION.
The developmental and clinical impacts of T21 in the population with DS are highly variable, with a large number of co-morbidities showing increased prevalence in this population relative to typical people. Despite many research efforts in this area, little is known about the molecular pathways that drive the various comorbidities common in DS. Clearly, identification of these pathways would facilitate the design of diagnostic and therapeutic strategies to serve this at-risk population via precision medicine approaches. An obvious impact of these approaches would be in the management of diverse neurological conditions showing increased prevalence in this population, including, but not restricted to, early onset AD (3, 10, 70, 71), epilepsy (72), depression (73), and autism (74, 75). Our results point to dysregulation of the KYN pathway as a potential contributing factor to the development of these conditions in people with DS, with obvious diagnostics and therapeutic implications as described below.
People with DS constitute the largest population with a strong predisposition to AD, which is attributed to the fact that the APP gene is located on chr21 (3, 70, 71, 76) , and that APP duplication causes familial early onset AD in the typical population (77). By age 40, virtually all individuals with DS present the brain pathology of AD; however, the age of dementia diagnoses is highly variable, with some individuals being diagnosed in their (106) and in an early transgenic mouse model of AD (107) . Based on these observations, we hypothesize here that those individuals with DS showing the strongest degree of dysregulation in the IFN➝IDO1➝KYN pathway will also display earlier onset and faster progression of AD. Clearly, testing this hypothesis will require a significant effort, including a multi-dimensional, longitudinal analysis of IFN signaling, KYN dysregulation, and various metrics of the AD pathological cascade.
Beyond AD, it is possible that KYN dysregulation is a driver of other neuropathologies more prevalent in DS, such as epilepsy/infantile spasms/seizures, depression, and autism (72-75). KYN and QA were shown to promote seizures in mice, rats, and frogs (108-111), and QA was found to be elevated in mouse models of epilepsy (112) , leading to the characterization of QA as an 'endogenous convulsant' with a pathogenic role in seizure disorders (113) . The role of tryptophan catabolism in depression is undisputed (114) , with a prominent role for serotonin depletion as a causative event, leading to the widespread therapeutic use of selective serotonin reuptake inhibitors (SSRIs). Importantly, activation of the KYN pathway shunts tryptophan away from serotonin synthesis, causing serotonin depletion, which led Lapin and others to propose the 'kynurenine hypothesis' of depression (115) . The discovery of the neurotropic activities of KYN and its derivatives indicated that induction of the KYN pathway could not only drive serotonin deficiency, but also promote depression-associated anxiety, psychosis, and cognitive decline (116) . Notably, it has been amply documented that therapeutic administration of IFN-α can induce depression (117) (118) (119) . During therapeutic use of IFN-α for the treatment of hepatitis C, high tryptophan breakdown was associated with depression-like symptoms during the course of treatment, leading Wichers et al. to propose that IDO1 induction (and consequent neurotoxicity) was the principal pathophysiological mechanism (50, 120). Regarding autism, independent cohort studies have documented dysregulation of KYN metabolism in patients diagnosed with autism spectrum disorder (ASD) (121, 122) , as demonstrated by increased KYN/KA ratios (122) and elevated levels of QA (121) , adding further evidence to the growing notion of neuroinflammatory processes in the etiology of ASD (123) .
In addition to the recognized neurological conditions discussed above, KYN dysregulation could contribute to the cognitive deficits associated with DS. The acute effects of KYN metabolites, QA in particular, on cognitive function are well documented (16, 124) . QA is a potent neurotoxin that acts as an excitotoxic agonist of NMDA receptors, and which may also exert toxicity via oxidative stress (9) . Importantly, dysregulation of the KYN pathway in DS could explain a large body of work showing beneficial effects of memantine, an NMDA antagonist that protects from QA-mediated neurotoxicity (10-13), as well as anti-oxidants such as vitamin E, in various animal models of DS (125) (126) (127) (128) (129) . Of note, memantine is an approved drug for the treatment of AD, which is currently being tested in a follow-up Phase II clinical trial to improve cognition in young adults with DS (NCT02304302). The initial pilot trial showed benefits on a subset of neurocognitive measures (130) . A second independent trial, which focused on adults 40 years and older, showed no effects in any of the endpoints (131).
However, we posit here that the limited therapeutic effect of this drug is due to its action at a very downstream step in the pathway, and that inhibitors of IDO1 (107, 132) , kynurenine-3-monooxygenase (KMO) (133) , and IFN signaling (e.g. JAK inhibitors, decoy IFNR receptors) (134, 135) should be considered. Even if memantine is pursued further, we suggest that its use should be accompanied by an assessment of the degree of KYN dysregulation in those receiving the drug. In principle, memantine should have no benefits for individuals with DS who display normal levels of QA.
Finally, it is important to note that the KYN pathway plays major roles in immune control. KYN is a potent immunosuppressive metabolite promoting 'immune privilege' in tissues such as the brain, testes, and gut, but which is also exploited by some tumor types to evade immune surveillance (17, 136) . KYN upregulation in people with DS may affect key cell types involved in autoimmunity, such as regulatory T cells (17, 136) , and it may represent an immunosuppressive negative feedback mechanism downstream of chronic IFN signaling (46-49, 137) . Given that people with DS are highly predisposed to myriad autoimmune disorders, and that Pneumonia lung infections are the top cause of death in people with DS (138), our results justify future investigations to define the role of KYN dysregulation in multiple common co-morbidities in DS.
Materials and Methods

Human cohorts and sample collection
All human subjects in this study were consented according to Colorado Multiple Institutional Review Board (COMIRB)-approved protocols. Written informed consent was obtained from parents or guardians of participants under the age of 18, and assent was obtained from participants over the age of 7 who were cognitively able to 
Sample preparation
For plasma analyses (human and mouse plasma), a volume of 50 µl of was extracted in 450 µl of ice cold lysis buffer (methanol:acetonitrile:water 5:3:2). For cell experiments, 1x10
6 cells were extracted in 1 ml of lysis buffer.
In both protocols, incubation with lysis buffer was followed by vortexing for 30 minutes at 4ºC. Separate extraction for hydrophobic metabolites (including oxylipids) were performed in ice cold methanol with similar ratios and workflows. Insoluble proteins were pelleted by centrifugation (10 minutes at 4ºC and 10,000 x g) and supernatants were collected and stored at -80°C until analysis. UHPLC-MS metabolomics analyses were performed using a Vanquish UHPLC system coupled online to a Q Exactive mass spectrometer (Thermo Fisher, Bremen, Germany). Samples were resolved over a Kinetex C18 column (2.1 x 150 mm, 1.7 µm; Phenomenex, Torrance, CA, USA) at 25ºC using a three minute isocratic condition of 5% acetonitrile, 95% water, and 0.1% Compounds of interest were monitored and quantified in negative ion mode against deuterium-labeled internal standards. MS analysis and data elaboration were performed as described (139, 140) . To monitor possible technical variability, technical replicates were run for both cohorts. Briefly, for the plasma samples from each cohort, aliquots of each of the individual samples were combined to make technical replicates, which were run as described above. Additionally, in each experiment, several buffer aliquots were run as blanks for artifact identification.
Metabolomics data processing
Metabolite assignments and isotopologue distributions in tracing experiments with to fit a linear model to the data, including age, sex, and cohort as covariates (21) . Log fold change, p-value and adjusted p-value were calculated for the T21-D21 comparison using the empirical Bayes function and BenjaminiHochberg adjustment procedure for multiple testing correction in limma (143) . Adjusted p-values shown in the volcano plots and reported on the box plots were generated with this limma moderated t-test. For displaying data per sample on the boxplots, we plotted the residuals from the model fit.
For pathway enrichment, we first mapped the 91 metabolites to KEGG pathways using the KEGGREST R package (144) . Of the 91 metabolites, 79 were annotated to at least one KEGG pathway. In total, this resulted in 116 unique pathway annotations which had at least 1 metabolite in them from the set of 79. We excluded pathways with less than 5 metabolites in them, leaving 52 pathways to investigate. Using this set of pathways,
we performed a hypergeometric test in which the 16 differentially abundant metabolites were selected from the 79.
For each pathway, we tested the number of metabolites that were both in the pathway and differentially abundant.
Predictive modeling
To select metabolites to be used as features for predictive modeling, we used the age-, sex-, and cohort-adjusted metabolomics data. Missing values made up less than 1% of the data and were imputed with the k-nearest neighbors algorithm using k = 5. Imputation was performed within the karyotype group using the impute package in R (145). We trained 10,000 independent, 5-fold cross-validated lasso regression models on combined set of Nexus and HTP samples using the R, glmnet package (146) . For each independently trained model, metabolite coefficients and model accuracy was recorded. For models which reached 90% accuracy or greater, we recorded which metabolites had non-zero coefficients (i.e. features selected in the model). To select our final set of biomarkers to test, we used metabolites which had been selected by at least 80% of the models reaching 90% accuracy or greater, resulting in 11 total metabolites. We then evaluated the performance of building a predictor using the lasso model with the top 11 identified metabolites. To estimate performance, we ran a bootstrapped analysis over 10,000 independently trained models. We randomly separated the 169 patient samples into 80% training and 20% testing sets. Using the 11 metabolites, we used 5-fold cross-validation on the training set to identify the optimal value, then tested the trained model on the held-out testing set. We reported the average model performance over the 10,000 models and provide an empirically determined (from the bootstrapped analysis) 95% confidence intervals. Area under the receiver operating characteristic curve (AUC) is reported.
Data and code availability
All data and R code developed for the full set of statistical and machine learning analyses is available at:
https://github.com/CostelloLab/Trisomy21_KYN_metabolomics. To ensure reproducibility, this code can be run to generate all figures for this manuscript.
Cell culture
Human fibroblasts were described previously (11) . 
2 mg/mL IFN-α or 1x PBS to 120 mL of heavy labeled media. Cell lysates and media were collected at 0, 1, 6, and 24 hours following initial application of the heavy tryptophan and IFN-α. LC-MS metabolomics profiling was performed as described above, and tryptophan catabolites were identified by their C13 and/or N15 peaks.
Western blots
Cells were plated at equal densities (~33,000/cm Santos Franco, respectively. Animals were used between 6 and 30 weeks of age. All mice were maintained on a C57Bl/6 background and housed in specific-pathogen-free conditions. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Colorado Anschutz Medical Campus.
Poly(I:C) treatment
Mice were allocated into control and poly(I:C) groups according to age, sex, and genotype. VacciGrade TM high molecular weight poly(I:C) (InvivoGen Cat# vac-pic) was diluted to 1 mg/mL, according to manufacturer's Simplified schematic of tryptophan synthesis. Box and whisker plots showing model residuals (i.e. remaining component of the model fit after adjusting for, age, sex, and cohort), for which metabolites that increased in the T21 group are shown in red and metabolites that decreased in the T21 group are shown in blue. P-values were calculated using the linear model in Figure 1A adjusting for cohort, with age and sex as covariates, and using
Benjamini-Hochberg for multiple testing correction. 
